Skip to main content

MODULACION INMUNOFARMACOLOGICA DE LA INFLAMACION SISTEMICA ASOCIADA A DESORDENES METABOLICOS. BUSQUEDA DE NUEVAS DIANAS TERAPEUTICAS Y SINTESIS DE FARMACOS NOVEDOSOS

SAF2014-57845-R

•
Funding agency name Ministerio de Economía y Competitividad
Funding agency acronym MINECO
Program Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Call Proyectos I+D+i Retos de Investigación
Call year 2014
State Plan 2013-2016 Plan Estatal de Investigación Científica y Técnica y de Innovación
Management unit Secretaría de Estado de Educación, Formación Profesional y Universidades
Beneficiary centre FUNDACION PARA LA INVESTIGACION DEL HOSPITAL CLINICO DE LA COMUNIDAD VALENCIANA (INCLIVA)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publication Artículo científico (JournalArticle)

Machine Learning Model in Obesity to Predict Weight Loss One Year after Bariatric Surgery: A Pilot Study

  • Nadal, Enrique|||0000-0002-2808-298X
  • Ródenas, Juan José|||0000-0003-2195-7920
  • Benito, Esther
  • Ródenas-Navarro, Ana María
  • Palanca, Ana
  • Martinez-Hervas, Sergio
  • Civera, Miguel
  • Ortega, Joaquín
  • Alabadi, Blanca
  • Piqueras, Laura
  • Real, Jose T.
[EN] Roux-en-Y gastric bypass (RYGB) is a treatment for severe obesity. However, many patients have insufficient total weight loss (TWL) after RYGB. Although multiple factors have been involved, their influence is incompletely known. The aim of this exploratory study was to evaluate the feasibility and reliability of the use of machine learning (ML) techniques to estimate the success in weight loss after RYGP, based on clinical, anthropometric and biochemical data, in order to identify morbidly obese patients with poor weight responses. We retrospectively analyzed 118 patients, who underwent RYGB at the Hospital Clínico Universitario of Valencia (Spain) between 2013 and 2017. We applied a ML approach using local linear embedding (LLE) as a tool for the evaluation and classification of the main parameters in conjunction with evolutionary algorithms for the optimization and adjustment of the parameter model. The variables associated with one-year postoperative %TWL were obstructive sleep apnea, osteoarthritis, insulin treatment, preoperative weight, insulin resistance index, apolipoprotein A, uric acid, complement component 3, and vitamin B12. The model correctly classified 71.4% of subjects with TWL < 30% although 36.4% with TWL ¿ 30% were incorrectly classified as ¿unsuccessful procedures¿. The ML-model processed moderate discriminatory precision in the validation set. Thus, in severe obesity, ML-models can be useful to assist in the selection of patients before bariatric surgery., This research was funded by Instituto de Salud Carlos III, grant numbers PI15/00082, PIE15/00013, PI21/00220, and Conselleria de Educacion, Cultura y Deporte, Generalitat Valenciana, grant number AICO 2019/250 to L.P. and Prometeo/2021/046 to J.J.R. This work was also supported by Ministerio de Economia, Industria y Competitividad, grant number SAF2014-57845-R and by Ministerio de Ciencia e Innovacion, Agencia Estatal de Investigacion (MCIN/AEI/10.13039/501100011033) and Fondo Europeo de Desarrollo Regional (FEDER) (Project PID2022-141512NB-I00) to J.J.R. The authors also received financial support from CIBER de Diabetes y Enfermedades Metabolicas Asociadas (CIBERDEM), a research network of the Ministry of Health, Madrid, to J.T.R.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publication Artículo científico (JournalArticle)

Vitamin D Receptor Activation Reduces Angiotensin-II-Induced Dissecting Abdominal Aortic Aneurysm in Apolipoprotein E-Knockout Mice

  • Martorell-Tejedor, Sara
  • Hueso, Luisa
  • Gonzalez-Navarro, Herminia
  • Collado, Aida
  • Sanz, María-Jesús
  • Piqueras, Laura
[EN] Objective Abdominal aortic aneurysm (AAA) is a vascular disorder characterized by chronic inflammation of the aortic wall. Low concentrations of vitamin D-3 are associated with AAA development; however, the potential direct effect of vitamin D-3 on AAA remains unknown. This study evaluates the effect of oral treatment with the vitamin D-3 receptor (VDR) ligand, calcitriol, on dissecting AAA induced by angiotensin-II (Ang-II) infusion in apoE(-/-) mice. Approach and Results Oral treatment with calcitriol reduced Ang-II-induced dissecting AAA formation in apoE(-/-) mice, which was unrelated to systolic blood pressure or plasma cholesterol concentrations. Immunohistochemistry and reverse-transcription polymerase chain reaction analysis demonstrated a significant increase in macrophage infiltration, neovessel formation, matrix metalloproteinase-2 and matrix metalloproteinase-9, chemokine (CCL2 [(C-C motif) ligand 2], CCL5 [(C-C motif) ligand 5], and CXCL1 [(C-X-C motif) ligand 1]) and vascular endothelial growth factor expression in suprarenal aortic walls of apoE(-/-) mice infused with Ang-II, and all were significantly reduced by cotreatment with calcitriol. Phosphorylation of extracellular signal-regulated kinases 1/2, p38 mitogen-activated protein kinase, and nuclear factor-B was also decreased in the suprarenal aortas of apoE(-/-) mice cotreated with calcitriol. These effects were accompanied by a marked increase in VDR-retinoid X receptor (RXR) interaction in the aortas of calcitriol-treated mice. In vitro, VDR activation by calcitriol in human endothelial cells inhibited Ang-II-induced leukocyte-endothelial cell interactions, morphogenesis, and production of endothelial proinflammatory and angiogenic chemokines through VDR-RXR interactions, and knockdown of VDR or RXR abolished the inhibitory effects of calcitriol. Conclusions VDR activation reduces dissecting AAA formation induced by Ang-II in apoE(-/-) mice and may constitute a novel therapeutic strategy to prevent AAA progression., This study was supported by grants CPII13/00025, PI12/01271, PI15/00082, PIE15/00013, SAF2011-23777, and SAF2014-57845-R from the Carlos III Health Institute, the Spanish Ministry of Health, the Spanish Ministry of Economy and Competiveness, and the European Regional Development Fund (FEDER), an Intramural grant from INCLIVA, and research grants from the Generalitat Valenciana (GVACOMP2014-006 and PROMETEO II/2013/014).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Disruption of the CCL1-CCR8 axis inhibits vascular Treg recruitment and function and promotes atherosclerosis in mice

  • Vila Caballer, Mª Amparo
  • González-Granado, José M.
  • Zorita, V.
  • Abu Nabah, Y.N.
  • Silvestre Roig, Carlos
  • del Monte-Monge, A.
  • Molina-Sánchez, P.
  • Ait-Oufella, H.
  • Andrés-Manzano, María J.
  • Sanz, M. J.
  • Weber, C.
  • Kremer, Leonor
  • Gutiérrez Hernández, Julio
  • Mallat, Ziad
  • Andrés, Vicente
The CC chemokine 1 (CCL1, also called I-309 or TCA3) is a potent chemoattractant for leukocytes that plays an important role in inflammatory processes and diseases through binding to its receptor CCR8. Here, we investigated the role of the CCL1-CCR8 axis in atherosclerosis. We found increased expression of CCL1 in the aortas of atherosclerosis-prone fat-fed apolipoprotein E (Apoe)-null mice; moreover, in vitro flow chamber assays and in vivo intravital microscopy demonstrated an essential role for CCL1 in leukocyte recruitment. Mice doubly deficient for CCL1 and Apoe exhibited enhanced atherosclerosis in aorta, which was associated with reduced plasma levels of the anti-inflammatory interleukin 10, an increased splenocyte Th1/Th2 ratio, and a reduced regulatory T cell (Treg) content in aorta and spleen. Reduced Treg recruitment and aggravated atherosclerosis were also detected in the aortas of fat-fed low-density lipoprotein receptor-null mice treated with CCR8 blocking antibodies. These findings demonstrate that disruption of the CCL1-CCR8 axis promotes atherosclerosis by inhibiting interleukin 10 production and Treg recruitment and function., This study was supported by the Spanish Ministerio de Ciencia, Innovación y Universidades (MCIU, grants SAF2016-79490-R and SAF2014-57845-R) and the Instituto de Salud Carlos III (ISCIII, grants PI14/00526, PI17/01395, CP11/00145, and CPII16/00022) with co-funding from the European Regional Development Fund (ERDF, “Una manera de hacer Europa”), the Fundación Ramón Areces, European Union (EuroCellNet COST Action CA15214) and the INSERM. VZG is supported by the ISCIII, JMG-G by the ISCIII Miguel Servet Program and the Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), AdMM by the MCIU (predoctoral contract BES-2014-06779), and ZM by a British Heart Foundation Professorship. The CNIC is supported by the MCIU and the Pro CNIC Foundation and is a Severo Ochoa Center of Excellence (SEV-2015-0505)., Peer Reviewed